Fulvestrant

For research use only.

Catalog No.S1191 Synonyms: ICI-182780, ZD 9238

78 publications

Fulvestrant Chemical Structure

Molecular Weight(MW): 606.77

Fulvestrant (ICI-182780, ZD 9238) is an estrogen receptor (ER) antagonist with IC50 of 0.94 nM in a cell-free assay. Fulvestrant also induces autophagy and apoptosis and has antitumor activity.

Size Price Stock Quantity  
10mM (1mL in DMSO) RMB 533.25 In stock
RMB 567.34 In stock
RMB 2233.34 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Fulvestrant has been cited by 78 publications

Purity & Quality Control

Choose Selective Estrogen/progestogen Receptor Inhibitors

Biological Activity

Description Fulvestrant (ICI-182780, ZD 9238) is an estrogen receptor (ER) antagonist with IC50 of 0.94 nM in a cell-free assay. Fulvestrant also induces autophagy and apoptosis and has antitumor activity.
Targets
ER [1]
(Cell-free assay)
0.94 nM
In vitro

Fulvestrant is an effective inhibitor of the growth of ER-positive MCF-7 (with IC50 of 0.29 nM) but with no effect on the growth of ER-negative BT-20 human breast cancer cells. Fulvestrant causes accumulation of cells in G0/G1 and also reduces the proportion of cells capable of continued DNA synthesis. [1] Fulvestrant competitively inhibits binding of oestradiol to the estrogen receptor. Fulvestrant blocks nuclear localization of the ER through impairing receptor dimerisation, and energy-dependent nucleo-cytoplasmic shuttling. Because of the instability of fulvestrant-ER complex, the binding of Fulvestrant with ER finally results in accelerated degradation of the ER protein. [2] Fulvestrant (10 nM) not only decreases IGF-IR mRNA levels but also decreases the half-life. [3] Treatment with 100 μM Fulvestrant leads to a time dependent increase of TNFR1 and TRADD steady-state mRNA levels in MCF-7 cells. [4] Fulvestrant is capable of down-regulating androgen receptor expression and diminishes androgenic responses in LNCaP human prostate cancer cells. Fulvestrant also significantly attenuates R1881-stimulated growth by 70%. [5] Fulvestrant is able to modulate mitosis and cell death in immature cerebellar neurons via rapid activation of MAPK. [6]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MCF-7 NUnMNpNWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFTKUooyNjNvMUCwNEBvVQ>? NI\sNFY1QCCq NV;0dFZrcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NFHsVYczPDl5OUK5OC=>
MCF-7/LTED NGLGSVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1\Qb|EvOy1zMECwJI5O NIjpS3c1QCCq MVXpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NG\1cWIzPDl5OUK5OC=>
HCC1428 NWLjdYh7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1HrVlEvOy1zMECwJI5O MlvROFghcA>? MnH2bY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> M1PCO|I1QTd7Mkm0
HCC1428/LTED MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVexMlMuOTByMDDuUS=> NUC3dZJbPDhiaB?= NHrteo5qdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? M33lTFI1QTd7Mkm0
LCC1 NWPTV3BuTnWwY4Tpc44hSXO|YYm= MmL2NVAxKG6P NXPHT|J3PDhvMUS0JIg> NVToV28y[WO2aY\heIV{KFWSUjDzbYdv[Wyrbne= MYWyOFg2QDJ5Nx?=
LCC9 MlPESpVv[3Srb36gRZN{[Xl? MY[xNFAhdk1? NU\nZ2xoPDhvMUS0JIg> M1jFTIFkfGm4YYTld{BWWFJic3nncoFtcW6p MX[yOFg2QDJ5Nx?=
MCF-7  NVL0XXd5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEjTcWsyODBibl2= MomzOUBl MXPpcohq[mm2czDj[YxtKGe{b4f0bEB1dyBzMP-8iS=> MmSxNlQ5OTl3NUC=
mesangial  M4TETmZ2dmO2aX;uJGF{e2G7 NGe5O5cxNjFvMUCwJI5O MkG5OFghcA>? NI\hS4V{fXCycnXzd4V{KFSJRj5OtlEucW6mdXPl[EB1gXCnIFnWJINwdGyjZ3Xu NGfEPVkzPDd7M{[zPS=>
Mesangial M2rpe2Z2dmO2aX;uJGF{e2G7 MVuwMlEuOTByIH7N NETMcoIxNjViaB?= M3Owb4lvcGmkaYTzJHRITi4QskGtbY5lfWOnZDDTcYFlOiCyaH;zdIhwenmuYYTpc44hfmmjIFfQSXI> NETVcGMzPDd7M{[zPS=>
ER+ MCF-7/2a NVXPU45ZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGPmdodKSzVyPUCuNFA1KM7:TR?= NUPyNXNlOTV|MkS4PFQ>
ER+ MCF-7 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGf4cXYzODBiaB?= NVLJNGYyUUN3ME2wMlIyKG6P MlvUNVU{OjR6OES=
MCF-7  NVnlZYN1TnWwY4Tpc44hSXO|YYm= MVmxNOKhdk4EoB?= NXrJcFFwPzJiaB?= MWLy[ZZmenOnczD0bIUh\XO2cn;n[Y4h\W[oZXP0LGlEPTBiMT65JOOYKDFy4pkSPUBOMQ>? MkP4NlQ6ODh4NUK=
MCF-7  MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnvrTWM2OMLib3[gZZBxem:6aX3heIVtgSB{IH7N M4nwW|I{PDR6M{S2
H1975  NHHF[XZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoXuN:Kh|ryP MX:xJI0> NIPWdnZqdmO{ZXHz[ZMhfGinIHfl[ol1cW6rYjDz[Y5{cXSrdnn0fUBw\iCKMUm3OUBk\Wyuc9Mg MXyyOFI3QDhzMB?=
H1975 M4HWUGZ2dmO2aX;uJGF{e2G7 MmftN:Kh|ryP MYGxJI0> Mni0eZBz\We3bHH0[ZMhfGinIHzleoVtKG:oIFzleE04[w>? NY\nUGVjOjR{Nki4NVA>
MCF-7  NYTmTo5{TnWwY4Tpc44hSXO|YYm= NX\IW491OTBy4pEJcm3DqA>? NWXFZWdCPzJiaB?= NYnYXGdoemW4ZYLz[ZMhfGinIIDyc5Rm[3SrdnWg[YZn\WO2IH;mJGUzyqCrbjDj[YxtKGmwdnHzbY9v NF7SfYkzOzl|Nke3Ny=>
MCF-7  M3zUWWZ2dmO2aX;uJGF{e2G7 MWqxNFDjiImwTdMg M1uyNlI1NzR6IHi= NHXLNZln[WOrbHn0ZZRmeyCrbo\hd4lwdiC2aILveYdpKE2PUIOnJI1w\HWuYYTpc44> M{e2b|I{QTN4N{ez
BT474-tet-shMED1 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3;n[|AvOS13IN88US=> NIDzZZk4KGR? MoXabY5kemWjc3XzJEtFd3hiaX7keYNm\CClZXzsJIRm[XSqIHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ M{jGUlI{QTN4MkO0
ZR75-1-tet-shMED1  NW\vUHgzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3LQdlAvOS13IN88US=> MVq3JIQ> MUjpcoNz\WG|ZYOgL2RwgCCrbnT1Z4VlKGOnbHyg[IVifGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MlP5NlM6OzZ{M{S=
MCF-7-tet-shMED1 M4jDUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWrxepdmOC5zLUWg{txO Mon6O{Bl NYPyb4tlcW6lcnXhd4V{KCuGb4igbY5lfWOnZDDj[YxtKGSnYYToJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy Mn\hNlM6OzZ{M{S=
HepG2  MYrGeY5kfGmxbjDBd5NigQ>? NXywZXVrOC5yMT2xNEDPxE1? NEjJ[XMyQCCqwrC= MV\hZ5RqfmG2ZYOgeIhmKEWURT3t[YRq[XSnZDD0doFve2O{aYD0bY9vKG:oIFHGNmVT NGLXOoIzOzd|M{G4PC=>
MCF-7L  M3vqfmZ2dmO2aX;uJGF{e2G7 M3jBNFExOCCwTdMg NF;l[pMyOCCvaX6vNlQhcC92ODDo M3jB[5Jme3WudIOgbY4hTUeIUjygTGVTOiCjbnSgTGVTOyCyaH;zdIhwenmuYYTpc44h[XRicILvcI9v\2WmIHX4dI9{fXKn MnrINlM3QDZ2MU[=
MCF-7L  MWPGeY5kfGmxbjDBd5NigQ>? MWOxNFAhdk4EoB?= NVHMbmI{PDhiaB?= NWfLSoNScW6mdXPld{B2eHKnZ4XsZZRqd25ib3[gcXJPSSCxZjDFS2ZTKGyrZ3Hu[EBJSi2HR1[= MVKyN|Y5PjRzNh?=
MCF-7L M4X5[2Z2dmO2aX;uJGF{e2G7 MYSxNFAhdk4EoB?= MknYOFghcA>? NVLETFROcW6mdXPld{BGT0[UIH\hcYltgSCvZX3i[ZIh[WO2aY\heIlwdiC{ZYH1bZJm\CCHUh?= NX;oOVZSOjN4OE[0NVY>
C4-12  MonySpVv[3Srb36gRZN{[Xl? M1LTU|ExOCCwTdMg MUW0PEBp M1jLS4lv\HWlZYOgSWdHWiCoYX3pcJkhdWWvYnXyJIFkfGm4YYTpc44hemWzdXny[YQhTVJ? MUiyN|Y5PjRzNh?=
MCF-7L NX3WbVlyTnWwY4Tpc44hSXO|YYm= MVexNFAhdk4EoB?= NF;QZ2UzPCCq M1iwbYlv\HWlZYOgSWdHWiCyaH;zdIhwenmuYYTpc44hemWzdXny[YQhUEJvRVfGJIZ2dmO2aX;u NV6xcpNvOjN4OE[0NVY>
MMQ  M1nNZmZ2dmO2aX;uJGF{e2G7 NUnLNXdkOC14MkWgcm0> MnzRO|IhcA>? MnX4[I94di2{ZXf1cIF1\XNidHjlJIV5eHKnc4Ppc44hd2ZiZYP0do9o\W5icnXj[ZB1d3JvzsGgLGVT|rFr MVSyN|UzOzN3Nx?=
H1975  MmjaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3[xXFAvOzF{NT2xNEDPxE1? NFOyVJo3KGR? NHS1PVVqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NUDrdldQOjN|OUm5OVc>
H1975  NXr6[FNxSXCxcITvd4l{KEG|c3H5 MWSyNFAhdk1? MojZO|IhcA>? M{H6Z4VvcGGwY3XzJIVzdG:2aX7pZkBqdmS3Y3XkJIFxd3C2b4Ppdy=> NVTXc|BLOjN|OUm5OVc>
MCF-7  MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEnSfGwyOC9zMECvNVAxOCCwTR?= M{[wZ|IwPC94IHS= NXXFTYNsTE2VTx?= M1LnRYlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHLveIgh\G:|ZT2gZY5lKHSrbXWtJIRmeGWwZHXueEBu[W6wZYK= NETIdFEzOzNzM{WwOi=>
MCF-7  MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXSxNFAhdk1? MWO0JIQ> NWXE[opXTE2VTx?= Mnu3bY5lfWOnczDhJIhq\2incjDwdo9xd3K2aX;uJI9nKGOnbHzzJIlvKHSqZTDHNUBxcGG|ZdMg MUOyN|MyOzVyNh?=
MLO-Y4  MVfGeY5kfGmxbjDBd5NigQ>? MVyxxsDPxE1? MlPtNUBp NF25enNqdmirYnn0d{BGOi2rbnT1Z4VlKEO6NEOg[ZhxemW|c3nvci=> NYXqXVFwOjN{NEewOVc>
MCF-7 NIXtZlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYKxNFAhdk1? NGrKVYs1QCCq Mo\nZYJzd2ejdHXzJJRp\SCycn;sbYZmemG2aY\lJIVn\mWldDDv[kBud2SncnH0[UBvcXS{b4PheIl3\SC|dILld5M> MWSyN|IyPjd2NB?=
TG1-1  NIn5O5lHfW6ldHnvckBCe3OjeR?= MnXBNeKh|ryP M2rRZlI1KGh? NYrGSJNx[WK{b3fheIV{KEV{wrDpcoR2[2WmIHHjZ5VufWyjdHnvckBw\iCKSV[tNe6y MYeyN|A5QDZyNx?=
TG1-1  M2e0TWZ2dmO2aX;uJGF{e2G7 Ml\GNeKh|ryP MY[yOEBp M2O5ToFjem:pYYTld{BGOsLiaX7keYNm\CCjY3P1cZVt[XSrb36gc4YhWEl|Sx?= MUKyN|A5QDZyNx?=
MCF7 MojuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUixNFAhdk1? NE\OTXU1QCCq NXG0bXBbdGWjZIOgeI8h[SC|aX3pcIFzKGyxc4OgbY4he3W{dnn2ZYwh[XNid3n0bEBld3ixcoXibYNqdiCjbH;u[S=> MVGyN|A4PzJ2OR?=
MCF7 MnLyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVfyU2lROTByIH7N Ml:zOFghcA>? NXvwcVVQ\W6qYX7j[ZMhdnW2bHnuMY1m\GmjdHXkJINmdGxiZHXheIg> NFTrRlgzOzB5N{K0PS=>
MCF-7  M4TsdGZ2dmO2aX;uJGF{e2G7 MlL0OkBp NWTkXZVUTE2VTx?= NFHTWldifHSnboXheIV{KHSqZTDmcJVlcW:6b37pcE0hd3JiZnXubIV5[W2rZD3pcoR2[2WmIHnuZ5Jm[XOnIHnuJI1qWi1{MTDlfJBz\XO|aX;u NYO2TGV6OjNyNUKwN|Y>
MCF-7 NXjqco46T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWqxNFAhdk1xMTFOwG0> M173UFUh\A>? MnPHbY5pcWKrdIOgeIhmKHO2aX31cIF1cW:wIH;mJFE4|rJvZYP0doFlcW:u NHPyOJgzOjl6Mke2OS=>
MCF-7 NGH1T21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoTqNVAxKG6P NF;x[VI2KGR? NHTNNYRqdmirYnn0d{B1cGVic4TpcZVt[XSrb36gc4Yh\nW|YYLp[YxqdiCK MU[yNlk5Ojd4NR?=
1471.1 M16zemZ2dmO2aX;uJGF{e2G7 MYqxNFAhdk1? MnTqNUBp MX7FeG9JyqB? NV\kXVRlfGGtZYOgc44h[SCydX7jeIF1\SC|dHHpcolv\yCyYYT0[ZJv M4PUOFIzQDZ7MUC2
MCF-7 NHvFWoFHfW6ldHnvckBCe3OjeR?= NYXHbGVROTByIH7N NH\rWW8yKGh? MUHFeG9JyqB? MX30ZYtmeyCxbjDhJJB2dmO2YYTlJJN1[WmwaX7nJJBifHSncn6= NWDxUop[OjJ6NkmxNFY>
HeLa MX7GeY5kfGmxbjDBd5NigQ>? MmO4NVAxKG6P MXOxJIg> NEfPfoZGfE:KwrC= NE\ubmR1[WunczDvckBiKHC3bnP0ZZRmKHO2YXnubY5oKHCjdITldo4> M3O2SlIzQDZ7MUC2
COS-7  M3PNd2Z2dmO2aX;uJGF{e2G7 NI\peIgyODBibl2= M2Tld|EhcA>? MXHFeG9JyqB? NWPZcXE4fGGtZYOgc44h[SCydX7jeIF1\SC|dHHpcolv\yCyYYT0[ZJv MnXqNlI5PjlzME[=
BG1L-OHTLT  NVzTd3d4TnWwY4Tpc44hSXO|YYm= M3vLd|ExyqCwTR?= Mnr4NlTDqGkEoB?= NF7rUlVqdmirYnn0d{BGWs7zIHX4dJJme3Orb36= MWiyNlY2OjV3OB?=
BG1L-ICILT NEPTeVNHfW6ldHnvckBCe3OjeR?= NGSxT|UyOMLibl2= MUiyOOKhcMLi NYn2dplTcW6qaXLpeJMhTVMQsTDlfJBz\XO|aX;u M1;MelIzPjV{NUW4
PC-9 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUGwMlAxOy1|MDFOwG0> NXu0OmNlPDhiaB?= MoL6bY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> MXGyNlU3ODZ|NB?=
H1650 NF\CeW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUPo[VhuOC5yMEOtN|Ah|ryP MXW0PEBp NFPLRWJqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? M{DxWVIzPTZyNkO0
H1975 NEL1PFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3;zUVAvODB|LUOwJO69VQ>? NFe1VlM1QCCq MonwbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NHvpT3MzOjV4ME[zOC=>
H1975 NVWyeoZPTnWwY4Tpc44hSXO|YYm= NYXQT5BtO8LizszN MlqxN{Bp NGHqWGxi[nKxZ3H0[ZMhfGinIIDoc5NxcG9vRVfGVkBqdmS3Y4Tpc44h[nliZYP0do9o\W5? NHXhVWszOjV4ME[zOC=>
H1975 M1TNNmZ2dmO2aX;uJGF{e2G7 M4TPTlPDqM7:TR?= M3rOVVch\A>? NWnqT5hqcW6mdXPld{BGT0[UIHX4dJJme3Orb36= NGPFT5czOjV4ME[zOC=>
HTR-8 MnL5SpVv[3Srb36gRZN{[Xl? M4XGS|HDqM7:TR?= MknpNU01QCCq Mmr1[I94di2{ZXf1cIF1\XNidHjlJIV5eHKnc4Ppc44hd2ZiSVfGRnA4KG2UTlG= MXGyNlM5OzFzMR?=
JEG-3 NHvvPWtHfW6ldHnvckBCe3OjeR?= MWSxxsDPxE1? NWrF[lVsOS12ODDo MVPkc5dvNXKnZ4XsZZRmeyC2aHWg[ZhxemW|c3nvckBw\iCLR1\CVFchdVKQQR?= M4LjclIzOzh|MUGx
Huh7 MVfGeY5kfGmxbjDBd5NigQ>? NXPLeZpUPTEEoN88US=> NV30VFVuPDhiaB?= MWrpcohq[mm2czDn[Y5qe3SnaX6tcYVlcWG2ZXSgVG9POSC2cnHud4FkfGm4YYTpc44> MY[yNlMxPDJ7Nh?=
201T NYT0e5JLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1;2PFUh|ryP NYW4OYdDPzJiaB?= NX3a[npNcW6qaXLpeJMh[2WubDDndo94fGhic3nncolncWOjboTsfUBkd22kaX7l[EB4cXSqII\hcoRmfGGwaXK= NYLMXZlmOjJ{NUi0O|Y>
A549  M2PhZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXPQ[VFKPSEQvF2= NVnY[FdIPzJiaB?= M{LTcolvcGmkaYTzJINmdGxiZ4Lve5RpKHOrZ37p[olk[W62bImgZ49u[mmwZXSge4l1cCC4YX7k[ZRidmmk NWDJXVNyOjJ{NUi0O|Y>
MCF-7 Mn7jSpVv[3Srb36gRZN{[Xl? M1zZXFHDqM7:TR?= NFvxTJMzPCCqwrC= NWHFOVh[\G:5boLl[5Vt[XSnczDFVkBmgHC{ZYPzbY9vKGmwZIXj[YQh[nliND3PTE1VKMLi NV7Vc|JjOjJyNEmzNVY>
HCC-1428 Mmm1SpVv[3Srb36gRZN{[Xl? Ml3xNeKh|ryP MV2yOEBpyqB? MVLkc5dvemWpdXzheIV{KEWUIHX4dJJme3Orb36gbY5lfWOnZDDifUA1NU:KLWSgxsA> NYL3SHlGOjJyNEmzNVY>
MDA-361 M4r5VWZ2dmO2aX;uJGF{e2G7 MoTRNeKh|ryP M4CwN|I1KGkEoB?= M1vEfYRwf26{ZXf1cIF1\XNiRWKg[ZhxemW|c3nvckBqdmS3Y3XkJIJ6KDRvT1itWEDDqA>? NYe3PHpPOjJyNEmzNVY>
ZR75-1 MYrGeY5kfGmxbjDBd5NigQ>? M4KyO|HDqM7:TR?= NIn3fVEzPCCqwrC= NYfF[nNm\G:5boLl[5Vt[XSnczDFVkBmgHC{ZYPzbY9vKGmwZIXj[YQh[nliND3PTE1VKMLi M3\2cVIzODR7M{G2
MCF-7 NXznSlVtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFf0O4syyqEQvF2= MWi1MVExKGR? NYjoOYV7e3WycILld5NmeyCHMj3pcoR2[2WmIHfyc5d1cCCrbnjpZol1cW:w NI\2bIgzOjB2OUOxOi=>
HCC-1428 NWrrcW8xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHXNS44yyqEQvF2= MmnSOU0yOCCm MoHHd5VxeHKnc4Pld{BGOi2rbnT1Z4VlKGe{b4f0bEBqdmirYnn0bY9v M1vzOVIzODR7M{G2
MDA-361 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX2wWGRKOcLizszN M3zJbVUuOTBiZB?= Mnnpd5VxeHKnc4Pld{BGOi2rbnT1Z4VlKGe{b4f0bEBqdmirYnn0bY9v M4LGPFIzODR7M{G2
ZR75-1 Mn2wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV2xxsDPxE1? MVG1MVExKGR? NFf6cGV{fXCycnXzd4V{KEV{LXnu[JVk\WRiZ4Lve5RpKGmwaHnibZRqd25? NYDGdpJmOjJyNEmzNVY>
MCF-7/AC-1 M1L6[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH\YbG0xNTBwMjFOwG0> NVTtUodqPiCm NHjo[ZNqdmirYnn0d{Bk\WyuIHfyc5d1cCCvb3Tld5RtgQ>? MXSyNlA1Ojd7Mh?=
MCF7 NF23NI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn3nNVAhyrWP NIDCUI01QCCq MofpbY5lfWOnczDj[YxtKGmwaHnibZRqd25id3jpZ4gh[2GwIHLlJIVvcGGwY3XkJIJ6KG[rYoLvZoxie3S| MYeyNlA1OTh6Nx?=
MMQ NWnlZ3FOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYOwMVYzPSCwTR?= Ml:wO|IhcA>? MWLwdo9lfWOnczDzeIF1cXO2aXPhcIx6KHOrZ37p[olk[W62IHnubIljcXSrb36gc4Yh[2WubDDwdo9tcW[ncnH0bY9vyqB? MWWyNlAyPTFyMR?=
MMQ M2rzUGZ2dmO2aX;uJGF{e2G7 M4rFVFAuPjJ3IH7N NX\kbGI2PzJiaB?= MVrwdo9lfWOnczDhJJN1[XSrc4TpZ4FtdHlic3nncolncWOjboSsJIRwe2VvZHXw[Y5l\W62IILl[JVkfGmxbjDpckBRWkxic3XjdoV1cW:w MWSyNlAyPTFyMR?=
MCF7 NVrxNnBJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWDZfHRKOC1zIN88US=> NHXmdm8zPC1zMkCgbC=> NWLFN2RLcW6qaXLpeJMhfGinIHfyc5d1cCCxZjDNR2Y4NVmELUJCpC=> MUGyNVg3OzJ3OB?=
HepG2 MVvBdI9xfG:|aYOgRZN{[Xl? M2TvOVAvOcLizszN NVix[olFOjRiaB?= NYG1RYox[WKxbHnzbIV{KHSqZTDld5Rzd2enbj3pcoR2[2WmIIXwMZJm\3WuYYTpc44hd2ZiYYDvRWkh[W6mIHHwc20> NHr1N3ozOThzNkKzNy=>
MCF7–iFR3 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVTR[I9UOjBvMUCwJI5O MXe5OkBp MWTlcohidmOnczDBVE1qdmS3Y3XkJINmdGxiZ4Lve5RpKGmwaHnibZRqd25? MWOyNVc6Ojh6OR?=
MCF7S MnP2SpVv[3Srb36gRZN{[Xl? MXixxsDPxE1? NGD1V5o1QCCq NELw[3pld3ewcnXneYxifGW|IH;2[ZJidGxiRWNOtUBxem:2ZXnuJIxmfmWucx?= MmrnNlE2OzNzOUW=
MCF7 M{LTb2Z2dmO2aX;uJGF{e2G7 MYSxxsDPxE1? NULLZnEyPDhiaB?= MVjkc5dvemWpdXzheIV{KG:4ZYLhcIwhTVMQsTDwdo91\WmwIHzleoVtew>? M3LLNVIyPTN|MUm1
MCF7S NU\YcVU3TnWwY4Tpc44hSXO|YYm= MoXwNeKh|ryP M2XzWlch\A>? NFTHXY9ifHSnboXheIV{KHS3bX;yd5Bp\XKnIH\vdo1ifGmxbjDhcoQheHKxbHnm[ZJifGmxbh?= NX3pVlN7OjF3M{OxPVU>
MCF7S M1zpZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{PLOVAvPS9zIN88US=> MoX4O{Bl NH;lUlVFVVOR M2W3cYRm[3KnYYPld{Bk\WyuIHX4dIFve2mxbh?= NEP6ZoIzOTV|M{G5OS=>
T47D  MojGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlHVOEBvVQ>? M2PpbVQxKGh? Mlnxd5VxeHKnc4Pld{Bk\WyuIHfyc5d1cCCvb3TldoF1\Wy7 Ml;yNlE1QDB|OUG=
BT474  NVztdIhsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGW1R2c1KG6P NUfPW5YxPDBiaB?= MYTzeZBxemW|c3XzJINmdGxiZ4Lve5RpKG2xZHXyZZRmdHl? NYDFZXZkOjF2OECzPVE>
T47D  NUHKfFJoTnWwY4Tpc44hSXO|YYm= MU[xNEBvVQ>? NHrzW2M1OCCq NUXzeGc5\G:5boLl[5Vt[XSnczDFVu6yKHC{b4TlbY4> MlzWNlE1QDB|OUG=
BT474  M{LHeGZ2dmO2aX;uJGF{e2G7 MnPDNVAhdk1? MX20NEBp NWr6ZmF5\G:5boLl[5Vt[XSnczDFVu6yKHC{b4TlbY4> NY\mUWFuOjF2OECzPVE>
MCF7 Mn:3SpVv[3Srb36gRZN{[Xl? NV3FUYdZOTByIH7N NFPDdWw4KGR? NV63eWJTemWmdXPld{BGWs7zIHX4dJJme3Orb36gd4lodmmoaXPhcpRtgQ>? M37W[VIyOzl4MEm0
T47D  NF;5N2NHfW6ldHnvckBCe3OjeR?= Mo\WNVAxKG6P MY[3JIQ> NF;vPJpz\WS3Y3XzJGVT|rFiZYjwdoV{e2mxbjDzbYdvcW[rY3HueIx6 MX:yNVM6PjB7NB?=
BT474  M3\HdWZ2dmO2aX;uJGF{e2G7 NGnUUmEyODBibl2= NIXYTpg4KGR? MXzy[YR2[2W|IFXS{tEh\XiycnXzd4lwdiC|aXfubYZq[2GwdHz5 NHi2XpczOTN7NkC5OC=>
MDAMB361 MVHGeY5kfGmxbjDBd5NigQ>? MXmxNFAhdk1? MmmyO{Bl NVLH[mpxemWmdXPld{BGWs7zIHX4dJJme3Orb36gd4lodmmoaXPhcpRtgQ>? NIfsWXAzOTN7NkC5OC=>
MCF7 NEe2elRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGO0fI8xNjBzLUGg{txO MV[3JIQ> NUT2dFJGemWmdXPld{Bk\WyuIHfyc5d1cCC|aXfubYZq[2GwdHz5 MnLVNlE{QTZyOUS=
T47D  MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYCwMlAyNTFizszN NGni[IQ4KGR? MWPy[YR2[2W|IHPlcIwh\3Kxd4ToJJNq\26rZnnjZY51dHl? MUiyNVM6PjB7NB?=
BT474  NVfFdI9RT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWOwMlAyNTFizszN MmP2O{Bl NHiwcm5z\WS3Y3XzJINmdGxiZ4Lve5RpKHOrZ37p[olk[W62bIm= M17iR|IyOzl4MEm0
MDAMB361 NYW3ZYpGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFzNe2IxNjBzLUGg{txO Mni4O{Bl MWPy[YR2[2W|IHPlcIwh\3Kxd4ToJJNq\26rZnnjZY51dHl? NXLWR21xOjF|OU[wPVQ>
MCF7 Mn7tSpVv[3Srb36gRZN{[Xl? MoHrNVAxKG6P M{TrNlch\A>? NFXtV21qdmS3Y3XzJI9nKEW{YlKzJIFv\CCHcnLCOEBz\WOncITvdkBmgHC{ZYPzbY9vKGGwZDDzbYdv[WyuaX7n NVntb2x7OjF|OU[wPVQ>
T47D  NH3oZ3ZHfW6ldHnvckBCe3OjeR?= MnLENVAxKG6P MkLtO{Bl MVTpcoR2[2W|IH;mJGVz[kJ|IHHu[EBGemKENDDy[YNmeHSxcjDlfJBz\XO|aX;uJIFv\CC|aXfuZYxtcW6p M1XvflIyOzl4MEm0
BT474  NGHh[ZNHfW6ldHnvckBCe3OjeR?= NIHjTJIyODBibl2= M1zrc|ch\A>? NXHmXWg2cW6mdXPld{Bw\iCHcnLCN{BidmRiRYLiRlQhemWlZYD0c5Ih\XiycnXzd4lwdiCjbnSgd4lodmGubHnu[y=> NHLKeYozOTN7NkC5OC=>
MDAMB361 Mn[xSpVv[3Srb36gRZN{[Xl? NYfKbGJTOTByIH7N M4raRlch\A>? MoP5bY5lfWOnczDv[kBGemKEMzDhcoQhTXKkQkSgdoVk\XC2b4Kg[ZhxemW|c3nvckBidmRic3nncoFtdGmwZx?= NEf6WZUzOTN7NkC5OC=>
MCF7 MlHlSpVv[3Srb36gRZN{[Xl? NYj3eolNOTBibl2= NFzuWlk6PiCq NWjGUpQ2\G:5boLl[5Vt[XSnczDFVkBmgHC{ZYPzbY9vyqB? NXPRT5NOOjF|N{izN|M>
MDA-MB-231 MoTPSpVv[3Srb36gRZN{[Xl? M2L6TlExKG6P NYHvPJBHQTZiaB?= MXvkc5dvemWpdXzheIV{KEWUIHX4dJJme3Orb39CpC=> NHXC[VgzOTN5OEOzNy=>
SK-BR-3 M1;K[WZ2dmO2aX;uJGF{e2G7 Mn7DNVAhdk1? M2TBdlk3KGh? M{[4ToRwf26{ZXf1cIF1\XNiRWKg[ZhxemW|c3nvcuKh NYjTfnV6OjF|N{izN|M>
MCF-7 NV\OSVFkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYTETIk4OTByIH7N MoTxO|IwQTZiaB?= M4O3SoNifXOnczDj[YxtKGO7Y3zlJIFzemW|dB?= M1;GZVIyOjl7OE[y
MMQ MmjqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnOzNE4xODhvNkK1JI5O NXPq[IpHPzJiaB?= MUnpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCkb4ToJJRqdWVvIHHu[EBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NFP2elQzODdyMEe1OS=>
MMQ NYjiUlFvTnWwY4Tpc44hSXO|YYm= NGfJOnkxNjByOD22NlUhdk1? NXLSbVZQPzJiaB?= NIHtN5lqdmirYnn0d{BRWkxic3XjdoV1cW:wIHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ M{HXd|IxPzByN{W1
MMQ NXTmZ|h[TnWwY4Tpc44hSXO|YYm= NX3JXJVHOC5yND22NlUhdk1? MUO3NkBp M2TKSYlvcGmkaYTzJGVT|rFiZYjwdoV{e2mxbh?= MWqyNFcxODd3NR?=
MMQ MXTGeY5kfGmxbjDBd5NigQ>? MVuwMlA1NTZ{NTDuUS=> NF3STXE4OiCq NXTROZhrfXC{ZXf1cIF1\XNiVFfG{tI{KGGwZDDUS2bPulKLSTDlfJBz\XO|aX;u MUmyNFcxODd3NR?=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
MDM2 / ER; 

PubMed: 24747123     


MCF7 (A) and T47D (B) cells were cultured in the presence of different concentrations of fulvestrant (Fulv) for 66 h. ER and MDM2 were detected by Western blot and normalized to β-actin. The decrease in protein expression (shown relative to vehicle control treatment) after fulvestrant treatment was calculated for each drug concentration. *P < 0.05 compared to vehicle control treatment. 

p-ErbB3 Y1289 / ErbB3 / p-ErbB4 Y1056 / ErbB4 / p-AKT / AKT / p-ERK / ERK; 

PubMed: 21396094     


Western blots showing the effect of increasing concentrations of heregulin β1 (HRGβ1) (0.1 to 10 ng/ml for five minutes) on total and phosphorylated ErbB3, ErbB4, AKT and extracellular signal-regulated kinases 1 and 2 (ERK1/2) protein expression in MCF-7 and T47D cells, maintained for 7 days in the presence of either fulvestrant (100 nM) of vehicle control (ethanol). 

ErbB3; 

PubMed: 23999432     


Immunofluorescence of ErbB3 in cells cultured for 24 hours with or without fulvestrant. 

ERα; 

PubMed: 19815064     


Breast cancer cells were treated with different doses of ICI for 3 hours. The expression levels of ERα and actin were assayed by Western blot using anti-ERα and anti-actin antibodies.

24747123 21396094 23999432 19815064
Immunofluorescence
IGF-1R / Erα; 

PubMed: 19815064     


Confocal microscope study of fulvestrant-induced ERα and IGF-1R co-localization on the cell membrane in non-permeabilized condition. Cells were starved in 1% DCC medium for 24 hr and then treated with either vehicle (left) or ICI at 100 nM (right) for 15 min. Treated cells were fixed in 4% formaldehyde and stained with mouse monoclonal anti-IGF-1R antibody (a), rabbit polyclonal anti-ERα antibody (b), or nuclear staining with DAPI (c). The merged images are shown in d. Scale bar = 20 μm.

Snail / E-cadherin ; 

PubMed: 23936773     


E-cadherin and Snail protein localization in MCF-7 cells 48 h after treatment of cells with E2 and the tested agents. C: control (untreated cells); E2: cells treated with 17β-estradiol; Fulv: cells treated with E2 + 100 nM Fulv. The image is representative of three independent experiments using a magnification of 63X.

19815064 23936773
Growth inhibition assay
Cell viability; 

PubMed: 29787591     


MTT assay of MCF-7 cells treated with various concentration of fulvestrant. Statistically significant reduced the % viability in MCF-7 cells (One-way ANOVA; ****p < 0.0001).

29787591
In vivo Fulvestrant is devoid of uterotropic activity, and when co-administered with estradiol, it effectively blocks the uterotropic action of estradiol with ED50 of 0.06 mg/kg/day s.c. in immature female rats. A single s.c. injection of 5 mg of Fulvestrant suspension blocks completely the growth of MCF-7 xenografts. The growth of transplants of the BrlO human breast tumor is also suppressed effectively by 10 μM Fulvestrant. [1] Fulvestrant (10 mg/rat, s.c.) reduces the androgen receptor expression, ERK1/2 phosphorylation and cell proliferation in the rat ventral prostate. [7] Fulvestrant also displays anti-angiogenesis in the chick egg chorioallantoic membrane. [8]

Protocol

Cell Research:[1]
- Collapse
  • Cell lines: MCF-7 breast cancer cells
  • Concentrations: 2.9 nM
  • Incubation Time: 5 days
  • Method: MCF-7 cells are cultured in multiwell plates (24-well, seeding density 4 × 104) in minimal essential medium containing phenol red, insulin (10 μg/mL), and 5% charcoal-stripped fetal calf serum without additional estradiol. Fulvestrant and/or estradiol are added in fresh medium 2 days after seeding. Cultures are maintained for 5 days with one further medium change and growth is assessed by measurement of total cell protein at the beginning and end of treatment and compared with that of controls treated with ethanol (0.1%) alone.
    (Only for Reference)
Animal Research:[6]
- Collapse
  • Animal Models: The human breast cancer xenografts MCF-7 in nude mice
  • Dosages: 5 mg/mouse
  • Administration: s.c. injection
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (164.8 mM)
Water Insoluble
Ethanol ''100 mg/mL warmed
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
2% DMSO+30% PEG 300+2% Tween 80+ddH2O
For best results, use promptly after mixing.
0.4mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 606.77
Formula

C32H47F5O3S

CAS No. 129453-61-8
Storage powder
in solvent
Synonyms ICI-182780, ZD 9238
Smiles CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04524000 Not yet recruiting Drug: Alpelisib|Drug: Fulvestrant Advanced Breast Cancer Novartis Pharmaceuticals|Novartis October 1 2020 Phase 2
NCT04483505 Not yet recruiting Drug: Combination Rogaratinib + palbociclib + fulvestrant Breast Cancer Metastatic|Hormone Receptor Positive Malignant Neoplasm of Breast Fundacion CRIS de Investigación para Vencer el Cáncer|Bayer|Pfizer|Apices Soluciones S.L. October 1 2020 Phase 1
NCT04300790 Not yet recruiting Drug: Alpelisib|Drug: Metformin|Drug: Fulvestrant Breast Cancer MedSIR|Novartis June 30 2020 Phase 2
NCT04024436 Recruiting Drug: TAS-120|Drug: Fulvestrant Metastatic Breast Cancer|FGFR2 Amplification Taiho Oncology Inc. December 15 2019 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Is there any information for the half-life of fulvestrant (Cat No.S1191)?

  • Answer:

    S1191, is about 13.5 to 18.5 hours in vivo: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2750771/. The half life of these compounds in cell culture might be different and we generally recommend replenishing with fresh drug every 24-48 hours.

Estrogen/progestogen Receptor Signaling Pathway Map

Estrogen/progestogen Receptor Inhibitors with Unique Features

Related Estrogen/progestogen Receptor Products

Tags: buy Fulvestrant | Fulvestrant ic50 | Fulvestrant price | Fulvestrant cost | Fulvestrant solubility dmso | Fulvestrant purchase | Fulvestrant manufacturer | Fulvestrant research buy | Fulvestrant order | Fulvestrant mouse | Fulvestrant chemical structure | Fulvestrant mw | Fulvestrant molecular weight | Fulvestrant datasheet | Fulvestrant supplier | Fulvestrant in vitro | Fulvestrant cell line | Fulvestrant concentration | Fulvestrant nmr
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID